par
Kathy Mahdoubi, Senior Correspondent | November 04, 2009
The current clinical recommendation is that the dose of radiation to the chest wall and skin of breast cancer patients should be at less than 125 percent of the prescription dose. Hologic's new MammoSite ML device has been designed with three additional lumens, each positioned three millimeters parallel to the central lumen, which can be seeded so that the radiation isodose avoids critical anatomy of the breast.
"The oncologist can pull down the source and have it not be as high on the surface as it is with the one lumen," said Amante.
Ad Statistics
Times Displayed: 129813
Times Visited: 7378 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The MammoSite radiation therapy system was cleared by the FDA in 2002, and since then it has gone through a circuitous change of hands. MammoSite was bought by Cytyc in 2005 and then acquired by Hologic in 2007. With increasingly more radiation oncologists looking at partial breast irradiation as an alternative to whole breast irradiation, MammoSite radiation therapy and the new MammoSite ML device seem to be positioned well for the future. MammoSite ML went into limited release practice in October and expansion could be happening very soon, said Amante.
"We'd like to get this out to the masses, so to speak, by year end," he said.
The ASTRO annual meeting wraps up Thursday at Chicago's McCormick Place Convention Center.
Back to HCB News
